InvestorsHub Logo
Followers 3422
Posts 32269
Boards Moderated 1
Alias Born 07/08/2006

Re: tripil7z post# 94972

Tuesday, 08/23/2016 3:25:51 PM

Tuesday, August 23, 2016 3:25:51 PM

Post# of 97237
$CLVS..$22.92..up 27%. FDA accepts New NDA for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer. That priority review is huge!

Sheff's Station...All Aboard...Sign Up Here!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.